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Principle and Design of Pseudo-Natural Products  
George Karageorgis*,a, Daniel J. Foley*,b, Luca Laraia*,c, and Herbert Waldmann* 
Abstract: 
Natural products (NPs) are a significant source of inspiration towards the discovery of new bioactive compounds 
based on novel molecular scaffolds. However, there are currently only a small number of guiding synthetic 
strategies available to generate novel NP-inspired scaffolds, limiting both the number and types of compounds 
accessible. In this Perspective, we discuss a design approach for the preparation of biologically relevant small 
molecule libraries, harnessing the unprecedented combination of NP-derived fragments as an overarching strategy 
for the synthesis of new bioactive compounds7KHVHQRYHOµSVHXGR-QDWXUDOSURGXFW¶FODVVHVUHWDLQWhe biological 
relevance of NPs, yet exhibit structures and bioactivities not accessible to nature or through the use of existing 
design strategies. We also analyse selected pseudo-NP libraries using chemoinformatic tools, to assess their 
molecular shape diversity and properties. To facilitate the exploration of biologically relevant chemical space, we 
have identified design principles and connectivity patterns that would provide access to unprecedented pseudo-NP 
classes, offering new opportunities for bioactive small molecule discovery. 
Main text 
The search for small molecules with novel molecular scaffolds that display unprecedented or unexpected biological 
activity greatly benefits from insights gained from compound classes that are biologically relevant by definition, 
such as natural products (NPs). NPs have served as an inspiration and resource in drug discovery and chemical 
biology1 and constitute chemical matter pre-validated by evolution.2  
Libraries based on natural product structure or more relaxed chemical and structural considerations have been 
developed through different approaches. At one end of the spectrum NP-derived compound collections may be 
synthesised directly from readily available NPs, e.g. by derivatisations at pre-existing reactive sites, and by ring-
distortion and/or -modification approaches ³FRPSOH[LW\ WR GLYHUVLW\´ &W' as first demonstrated by 
Hergenrother.3,4 For instance, abietic acid was converted into a chemically diverse collection of complex 
compounds by means of 3-6 transformations, including ring opening-, expansion- and contraction sequences4 
(Figure 1a), whilst ring-distortion of the alkaloid quinidine yielded novel inhibitors of autophagy.5 In an alternative 
approach complex polycyclic scaffolds that exhibit NP characteristics and properties are directly synthesised and 
distorted. For instance, tropane-containing compounds delivered multiple new scaffolds not found within NPs, 
several of which were found to be novel bromodomain binders.6 
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At the other end of the spectrum, Diversity Orinted Synthesis (DOS) 7 following the build/couple/pair strategy, 
employs the robust asymmetric intermolecular coupling of building blocks to induce stereochemical diversity, 
followed by intramolecular pairing of complementary functional groups, resulting in skeletal diversity (Figure 1b). 
DOS is not directly based on NP structures. However, the chemically diverse DOS compound classes can be 
considered NP-like due to their higher stereochemical content and higher fraction of sp3-hybridised centers, when 
compared to commercial libraries. Incorporation of such NP-like characteristics positively contributes to biological 
performance of DOS libraries. 
Biology-oriented synthesis (BIOS) draws inspiration from NPs to inform the synthesis of biologically relevant 
compound collections based on simplified NP scaffolds.2 In BIOS, NP scaffolds are reduced in chemical complexity 
in a stepwise process, arriving at smaller intermediary scaffolds which then are employed as starting points for the 
synthesis of NP-inspired compound collections (Figure 1c). BIOS may be constrained by both chemical and 
biological limitations. Known and newly identified NPs occupy a large, definable, yet limited portion of chemical 
space.8 However, NP-like chemical space, in general, is much bigger such that the focus on NP-scaffolds limits 
BIOS. The capacity to produce previously unknown NPs using biosynthetic technologies has been demonstrated, 
for instance, by the application of horizontal gene transfer techniques to assemble new artificial biosynthetic 
pathways,9,10 and by the activation of transcriptionally silent biosynthetic pathways.11,12 From a biological 
viewpoint, scaffolds prepared under the guidance of BIOS may retain the same kind of bioactivity as the guiding 
NPs, limiting the exploration of biological space.9  
A design principle for bioactive compound discovery 
Design of novel compound classes that broadly retain the biological relevance of NPs will benefit from strategies 
that enable the rapid exploration of biologically relevant chemical space, in particular fragment-based compound 
design.13 The properties of NPs are retained in NP-derived fragments,14 NPs may already be fragment-sized,15 or 
can be converted into fragment-sized ring-systems.16 Therefore, unprecedented combinations and fusions of NP 
fragments may provide access to novel scaffolds that may retain the chemical and biological characteristics of NPs, 
yet extend beyond the biologically relevant chemical space explored by nature (Figure 1d). These compounds would 
FRQVWLWXWHµSVHXGR-QDWXUDOSURGXFWV¶EHFDXVHWKHVHQRYHO13-inspired scaffolds would not be accessible through 
biosynthesis. Compound collections based on such molecular scaffolds, and, therefore, inspired by natural products 
may have different properties compared to both naturally occurring small molecules and BIOS collections, and may 
display unprecedented biological activities.
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The term pseudo-natural product has been previously used by Suga et al. to describe cyclic peptides,17,18 and by 
Oshima et al. for products of intercepted biosynthetic pathways.19,20 We use the term for small molecule compound 
libraries based on scaffolds derived through the unprecedented combinations of NP fragments. Here we describe 
key principles to guide the design of such compound libraries and provide a first chemoinformatic analysis showing 
that pseudo-NPs may provide access to previously unexplored areas of biologically relevant chemical space, and 
show that pseudo-NPs can be endowed with novel bioactivity. 
Figure 2 exemplifies the process for the design and actual synthesis of representative pseudo-natural product 
classes.21±26 In an initial design step, fragments characteristic for different natural product classes are identified and 
combined in unprecedented arrangements (Figure 2a; for a discussion of the criteria guiding design and fragment 
combination types, see below), and then syntheses are developed and executed that give access to the desired 
pseudo-NP classes (Figure 2b-f). Finally, bioactivity of the novel pseudo-NPs is determined in different 
biochemical and biological assays.  
Chromopynones 1 provide an illustrative example for pseudo-NP design and synthesis.21 They embody a bridged-
bicyclic scaffold which combines the fragments for widely occurring, bioactive chromane and 
tetrahydropyrimidinone NP-fragments. They were efficiently synthesised in a one-pot procedure involving a 
Biginelli reaction27 as key step (Figure 2b). In a further example, the biologically prevalidated tropane and indole 
fragments were combined by means of an enantioselective intermolecular 1,3-dipolar cycloaddition to furnish a 
new, structurally-rich scaffold, 2 (Figure 2c).22 Indoles and tropanes are characteristic of hundreds of NPs with 
widely differing bioactivities, but do not occur in combination in nature. Similarly, intermolecular 1,3-dipolar 
cycloadditions found use in the preparation of pyrrotropane pseudo-NPs 3 (Figure 2d), which fused the tropane and 
pyrrolidine fragment,23 and a related intramolecular 1,3-dipolar cycloaddition proved powerful for the preparation 
of pseudo-NPs 4, combining the pyrrolidine and quinolone fragments (Figure 2e).24 The oxindole fragment and O-
heterocycles which are characteristic substructures of iridoid terpenes were combined to spiro-configured 
indiridoids by means of a Au(I) catalyzed reaction cascade including a 6-endo-dig ene-yne cyclization followed by 
ring-opening and rearrangement. A one-pot process including the use of an enantioselective Pictet±Spengler 
reaction was employed to fuse indoles with piperidone components to provide the bridged µLQGRSLSHQRQH¶
scaffold 5 (Figure 2f).  
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Chemoinformatic analyses of pseudo-natural products  
To characterise the chemical space occupied by these previously reported pseudo-NPs,21±26 we calculated the natural 
product-likeness scores (NP Score)28 for the pyrrotropanes,23 the pyrroquinolinones,24 and the indopipenones.26 We 
have reported the NP Score for chromopynones and indotropanes previously.21,22 We compared the collective NP 
Score of these compound libraries to the scores of the NPs found in the ChEMBL database,29 the set of approved 
drugs in DrugBank30 representing marketed and experimental drugs and selected BIOS libraries (see Supplementary 
Figure 7 and Supplementary Tables 13 and 14). The NP likeness score measures the frequency at which fragments 
occur in natural products as compared to commercial non-NPs. It ranges from -5 to +5, and higher values indicate 
higher natural product-likeness. To calculate the score the corresponding molecule is divided into atom-centred 
fragments. These contribute to the score by their relative frequency of occurrence in NPs divided by their frequency 
of occurrence in commercial non-NPs. BIOS compounds display a broad NP-score distribution ranging from 0.0 to 
+4.0 (Figure 3a, red curve) and overlay significantly with the set of natural products in the ChEMBL database, as 
expected. The pseudo-NPs display more narrow distributions with a range from í1.0 to +1.0 (Figure 3a, black 
curve) and cover a portion of chemical space only sparsely occupied by NPs. These scores may be rationalised by 
the fact that these new NP fragment combinations cannot be found in known NP scaffolds.  
Calculation of relevant molecular properties of pseudo-NPs  revealed that the majority of the pseudo-NP collections 
IDOOZLWKLQ³/LSLQVNLUXOHRI´5RVSDFH31 (60-100% for individual libraries, 86% for the collated collections; 
Figure 3b). Thus, unprecedented combinations of NP fragments may render pseudo-NP scaffolds to be fairly ³drug-
like´DQG pseudo-NP collections may, therefore, display advantageous physical properties for molecular discovery. 
This observation extends to other metrics of Ro5 space such as total polar surface area (62 ± 109 Å2), and H-bond 
donors and acceptors (0-3; and 0-10, respectively, see Supplementary Table 12 for further details). By comparison, 
only 48% of BIOS compounds fall within Lipinski-like space (Figure 3b), yet they have a higher Fsp3 compared to 
the currently explored pseudo-NPs. 
Assessment of the molecular shape diversity of pseudo-NPs by determination of the principal moment of inertia 
(PMI) plots revealed a systematic shift away from the rod-disk axis, towards more three-dimensional molecular 
shapes for the pseudo-NPs. Most synthetic molecules congest along the rod-disk axis,32 as exhibited by the 
collection of approved drugs in the DrugBank database (Figure 3c).  
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Structural Analyses of Pseudo-Natural Products  
NP-derived fragments may be combined using different connectivity patterns to generate new pseudo-NPs (Figure 
4). A monopodal or linear connection could be used to connect two fragments, such as the phenylpyrrolidinones, 6 
(Figure 4a) which have previously been explored as androgen receptor antagonoists.33 By analogy, polypodal 
connections will be possible, and perhaps limited by synthetic accessibility. Patterns leading to the generation of 
stereogenic centres, and more structurally complex scaffolds should be prioritised to capture the high 
stereochemical content of NPs in general. For example, in indotropanes 2, pyrrotropanes 3, and pyrroquinolines 4, 
two adjoining fragments are fused edge-on-edge, sharing two common atoms. This connectivity pattern is also 
observed in natural products e.g. the Murraya alkaloids 8 (Figure 4b).34 Connection of two fragments through only 
one atom in a point-on-point manner will result in the formation of a spirocyclic centre such as reported for the 
diazaspirodecane core of selective dopamine D3 receptor antagonists 9,35 (Figure 4c) and the NP (í)-horsfiline, 
10.36 Two fragments may share three or more common atoms, forming a bridged bicyclic scaffold (Figure 4d), as 
for instance in the chromopynones 1, and in the NP sespenine, 11.37 Also, two adjoining fragments may not share 
any common atoms, but may even have one or two linking atoms as intervening connection points (Figure 4e). The 
adjoining fragments may be connected through non-sequential atoms resulting in the formation of a bridged 
bipodal38 connection pattern. The indopipenone pseudo-NP class 5, is such an example, and similarly this pattern 
can be observed in the NP aspergillin PZ, 1239 (For a more extended list of connection types and their examples in 
NPs and pseudo-NPs see Supplementary Scheme 1). 
 
Pseudo-NP design principles 
Alternative connective combinations of a given set of NP-fragments can yield markedly different pseudo-NP 
scaffolds, such that appropriate design of pseudo-NP structure may enable wider exploration of chemical space. 
For the design of such pseudo-NP classes, several basic criteria will be generally applicable: 
(i) Since chirality is a defining property of many NPs and stereogenic content correlates with bioactivity,40,41 NP 
fragments may be combined in complexity-generating reactions leading to novel three-dimensional scaffolds 
amenable to further derivatisation. 
(ii) NP fragments with complementary heteroatom content should be combined, in particular nitrogen (more 
frequently found in drugs than in NPs) and oxygen (more frequently occurring in NPs).42  
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(iii) Combination of NP fragments derived from NPs with diverse bioactivities may maximise the biological 
relevance of the resulting pseudo-NP scaffold. 
(iv) Combination of biosynthetically unrelated fragments may be beneficial for novel bioactivity, since 
biosynthetically different NPs will have been synthesised by different enzymes, encoding different structural 
features that may facilitate binding to different proteins. 
Using these general criteria, we investigated regioisomers of the pyrrotropane 22-27, and pyrroquinoline 28-35 as 
five related but different illustrative examples (Figure 5a) and calculated their NP scores. We found that compound 
classes 25-27, and 34 and 35, had been synthesised before,6,43,44 while the rest of the investigated compound classes 
have not been reported. From this analysis three complementary, yet alternative principles emerged, which draw 
inspiration from scaffold hopping approaches in medicinal chemistry (Figure 5b-d):45 
 
Combination of a fragment set in different connectivities. Scaffolds would be composed of frameworks that are 
different at the graph46 level, implementing the  connectivity patterns outlined above e.g. edge fusion (for 
pyrrotropanes: 22; for pyrroquinolines: 28), spiro fusion (for pyrrotropanes: 23; for pyrroquinolines:  30), or bridged 
fusion (for pyrroquinolines: 33) (Figure 5a). Such frameworks exhibit remarkable differences between scores and 
offer an opportunity for the systematic exploration of new chemical space. For instance, there is almost one unit of 
difference in the NP-score between scaffolds 22 and 23, and almost two units between scaffolds 28 and 36 (Figure 
5a).  
 
Combination of fragments with the same connectivity pattern, but different regioisomeric connectivity 
points. The connectivity pattern between fragments would be maintained (i.e. the framework is the same at the 
graph46 level), but atoms within the resulting scaffold are subsequently alternated (at the graph-node46 level). For 
example, 31 and 32 are both spiro-fused pyrroquinolines connected through the 2- or 3-position of the 
tetrahydroquinoline fragment respectively and the 3-position of the pyrrolidine fragment, but the pyrrolidine is 
rotated around the piperidine ring. Scaffolds 30 and 31 are both spiro-fused pyrroquinolines connected through the 
2-position of the tetrahydroquinoline fragment, but through the 2- or 3-position of the pyrrolidine fragment (Fig. 
5c), i.e. the nitrogen atom is rotated around the pyrrolidine ring. Scaffolds designed accordingly (e.g. for 
pyrrotropanes: 23, 24; for pyrroquinolines: 28-29) tend to cluster together in the NP-score analysis (e.g. there are 
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only 0.09 units of difference between scaffolds 28 and 29, Fig. 5a). However, despite exhibiting similar NP-scores, 
these regioisomeric scaffolds might exhibit different biological activities. 
More than two fragments can be combined in several distinct connectivity patterns. Although combinations 
of several fragments will lead to higher molecular weight compounds, such pseudo-NPs may still be very valuable.  
An example for a combination of an oxindole, a pyrrolidine, and a dihydroquinolinone fragment using spiro and 
edge fusions is shown in Figure 5d (37). 
For validation of these design criteria, a full set of isomeric scaffolds would have to be synthesised and broadly 
evaluated for bioactivity. For the isomeric compound classes shown in Figure 4 a literature search revealed that the 
corresponding data are not availalble. However, pyrrotropanes 26 have been identified as bromodomain binders,6 
whilst pyrroquinolines 34 are active against the retinoid orphan receptor-J(ROR-J),44 showing that different 
fragment combinations may lead to different bioactivity. Further analysis of the literature indicates that pseudo-NP 
structures have indeed been synthesised, but not yet in a consistent and complementary manner. Examples include 
indole-bridged chroman oxindoles by Bu et al.47 and 3,4-dihydropyrrolopyrazinones by Zhang et al.48 We note that 
the synthesis of such complementary pseudo-NP libraries will require and be facilitated by the development of 
novel, innovative synthesis methodologies. The pseudo-NPs synthesised in our laboratories will be stored and 
curated by the Compound Management and Screening Center of the Max Planck Gesellschaft (COMAS, see 
http://comas.mpi-dortmund.mpg.de/index.php) through which they are accessible in collaborative scientific 
projects. 
 
Biological evaluation of pseudo-natural products 
Pseudo-NPs may display unexpected bioactivities differing from the activities of the NPs from which their 
fragments are derived which calls for investigation of these compounds in assays monitoring wide biological space. 
For instance, the pseudo-NPs described in Figure 2 were investigated21,22,26 in cell-based assays that monitor 
progression through different signaling cascades (e.g. Wnt, Hedgehog) and phenotypic changes (e.g. lipid droplet 
formation, reactive oxygen species induction, autophagy). Such screens monitor changes in whole systems rather 
than individual biological targets and, due to their unbiased nature, can lead to the identification of novel protein 
targets.49   
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A phenotypic assay monitoring glucose uptake identified chromopynones 1 as novel glucose uptake inhibitors. 
Glucose metabolism is deregulated in cancerous tissue.50 Chromopynones exhibited a desirable dual GLUT-1,-3 
selectivity profile.21 Notably, compounds containing either of the underlying NP-fragments (chromane or 
tetrahydropyrimidinone), did not exhibit glucose uptake inhibitory activity. Thus, the chromopynone scaffold 
retains the biological relevance of the individual fragments, yet displays a different bioactivity profile. NPs 
containing both a chromane and a tetrahydropyrimidinone fragment have not been reported, suggesting that these 
fragments may be biosynthetically unrelated. The indotropane Myokinasib was identified as ATP-
competitive/mixed type myosin light chain kinase (MLCK1) inhibitors with an unprecedented inhibitor 
chemotype.22 MLCK1 is involved in inflammatory disease, myocardial infarction, as well as tumorigenesis.51 
Similar to chromopynones, the indotropanes emerge from a combination of biosynthetically unrelated NP-
fragments, leading to a novel pseudo-NP class with unprecedented biological activity. Indopipenones 5 were 
revealed to be inhibitors of MptpB tyrosine phosphatase26 and defined a novel phosphatase inhibitor chemotype. 
This enzyme plays a key role in the infection and proliferation of mycobacteria and it is a potential biological target 
for the treatment of tuberculosis.52 
 Beyond assays monitoring establishment of individual phenotypes, recently developed multiparametric high-
content image screening technologies,53  which quantify the changes of a wide number of cellular morphology 
characteristics, will be particularly suited to explore the biological activity of novel pseudo-NP classes. They 
combine the unbiased nature of phenotypic setups with the high information volume provided by high-content 
microscopy, and can be used to generate class- or compound specific phenotypic µfingerprints¶The fingerprint 
information may subsequently be used to extrapolate information about the biological target or mode-of-action of 
a small molecule, and may facilitate the realisation of pseudo-NPs as a more general design strategy for the 
discovery of bioactive compounds. 
Outlook 
Natural products continue to guide the design of new biologically relevant compound libraries, and NP structure 
has provided inspiration for different approaches aimed at the development of NP-like compound collections. DOS 
is not based on NP structures but mainly built on chemical and structural considerations. It employs robust 
transformations to build up stereochemically diverse compound libraries with high scaffold diversity and number. 
These are considered NP-like but their biological relevance is initially unclear. BIOS, pseudo-NPs and the CtD 
strategy, on the other hand, are built on genuine NP structures, and, therefore, are endowed with biological relevance 
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derived from their creation in evolution. Due to their biosynthetic origin and biological functions they encode 
structural properties that enable binding to proteins. In this sense, chemically diverse DOS libraries and compound 
collections directly delineated from existing NPs primarily differ in their origin and can be considered 
complementary. In this continuum pseudo-NPs occupy an intermediary position. On the one hand they are endowed 
with biological relevance (as are BIOS collections), on the other hand their fragment-based synthesis enables 
coverage of a larger area of chemical space (as do DOS libraries). 
Biological analysis of BIOS compound collections demonstrated that structurally simplified NP-inspired 
compounds can be endowed with diverse and interesting biological activities. Yet, BIOS is intrinsically limited 
both chemically and biologically due to its focus on specific NP scaffold structures. Combining BIOS with 
principles derived from fragment-based ligand discovery may enable the rapid exploration of biologically relevant 
chemical space beyond the areas accessible by known NP scaffolds, and give rise to new compound classes which 
are distinct from BIOS libraries. These synthetic, small molecule pseudo-natural products contain unprecedented 
combinations of NP-fragments.  
Here, we have analysed biologically active pseudo-NP libraries based upon scaffolds comprising novel 
combinations of NP-fragments. Chemoinformatic analyses employing the NP-score tool demonstrate that pseudo-
NP libraries occupy areas of chemical space not covered by NPs and BIOS libraries. The explored pseudo-NP 
libraries appear to have favourable physiochemical properties for molecular discovery.  
Using five related libraries21±26 as representative examples we have developed a set of design principles that can 
inform future syntheses of pseudo-NPs. A µthought experiment¶ suggested potential pseudo-NPs that would arise 
though unprecedented combinations of some simple NP-fragments (e.g. the pyrrolidine and quinoline ring-
systems). In general, multiple combinations of NP-fragments are possible, and pseudo-NPs have likely already been 
unknowingly prepared, but have yet to be studied in a systematic manner. Their synthesis is limited only by 
creativity and the tools available for their preparation. Therefore, the introduction of enabling synthetic 
methodologies that grant access to de novo combinations of NP-fragments will greatly facilitate pseudo-NP 
preparation and study. 
The examples of pseudo-NPs discussed here and their bioactivity profiles provide evidence that pseudo-NPs may 
display novel and unexpected bioactivities, different from their guiding NPs. However, for full analysis and 
exploration of pseudo-NP bioactivity, wider profiling is required in unbiased phenotypic screening platforms that 
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facilitate the identification of novel biological targets and modes of action. Use of such phenotypic and 
multiparametric screening platforms, e.g. WKH ³cell-painting assay´53, in combination with powerful target 
identification methods, such as proteome-wide thermal shift assays,54 or target degradation approaches,55 may 
facilitate target deconvolution for novel biological phenomena induced by compound treatment, and may realise 
the full value of pseudo-NPs towards bioactive compound discovery. We expect that new pseudo-NP classes will 
have significant value towards the exploration of biologically relevant chemical space, and ultimately towards 
molecular discovery programmes aimed at the modulation of disease.  
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Table of Contents Summary: 
In this Perspective we outline the principles for the design of novel and distinct compound classes emerging from 
de novo combinations of NP-derived fragments. These compounds are termed Pseudo-NPs, facilitate the 
exploration of biologically relevant chemical space and may have significant value for molecular discovery 
programs aimed at the modulation of disease. 
 
Figure Captions: 
Figure 1: Approaches to the design of biologically relevant compound collections. Panel a: Principle of the build-
couple-pair approach in Diversity Oriented Synthesis (DOS). This strategy results in compounds with high 
stereogenic/sp3 content displaying some NP characteristics; Panel b: Synthesis of natural product derived 
compounds by scaffold manipulation and decoration following the Complexity to Diversity (CtD) approach results 
in novel NP-derived compounds; Panel c: Scaffold synthesis and decoration following the principle of Biology 
Oriented Synthesis (BIOS) leads to  NP-inspired compounds; Panel  d: Design of pseudo-natural product collections 
by de novo combination of natural product fragments leads to NP-inspired compounds. 
Figure 2: Development of pseudo-natural product collections. Panel a: Rationale for the design of pseudo-natural 
product compound classes. Natural product fragments can be combined in unprecedented combinations to afford 
novel structures, e.g. indole with tropane, indole with piperazine etc. The individual fragment structures combined 
in the pseudo-NP scaffolds are colour coded. Panel b: Synthesis of chromopynones21 combining chromane and 
tetrahydropyrimidinone NP fragments. They are glucose uptake inhibitors with dual GLUT-1/-3 selectivity. 
Panel c: Synthesis of Indotropanes22 combining the indole and tropane NP fragments. They are mixed type MLCK1 
inhibitors. Panel d: Synthesis of Pyrrotropanes23 combining the pyrrolidine and tropane NP fragments. Panel e: 
Synthesis of Pyrroquinolinones24 combining the pyrrolidine and quinolinone NP fragments. Panel f: Synthesis of 
Indopipenones26 combining the indole and piperazine NP fragments. They are tyrosine phosphatase inhibitors. The 
individual fragments structures combined in the pseudo-NP scaffolds are colour coded. 
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Figure 3: Chemoinformatic analyses of pseudo-NPs. a: The NP-score for pseudo-NPs (black curve), the set of NPs 
from ChEMBL (red curve), approved drugs in the DrugBank database (blue curve) and selected BIOS libraries 
(green curve). Pseudo-NPs occupy a different area of the NP Score graph compared to NPs and fall under the 
distribution of compounds in DrugBank. b: Molecular properties analysis (ALogP vs MW) of pseudo-NPs (black 
squares) and BIOS libraries (green dots). A higher portion of Pseudo-NPs fall within the limits of Lipinski space 
compared to BIOS libraries. c: PMI plot of pseudo-NPs (black squares) and DrugBank compounds (green dots). 
Pseudo-NPs display a wide distribution of PMI values and move further away from the rod-disk axis of the graph 
compared to DrugBank compounds. For NP Scores, molecular properties analyses and PMI plots for individual 
Pseudo-NP classes, BIOS libraries NPs in ChEMBL and compounds in DrugBank please see SI, Supplementary 
Figures 1-7 and Supplementary Tables 1-17. 
Figure 4: Illustration of possible NP fragment connectivities to guide synthesis and design of pseudo-NPs. These 
connectivity patterns are also found in natural products, and characteristic examples are shown. a: Monopodal 
Connection: observed when two fragments are connected through a distinct atom in each fragment. b: Edge Fusion: 
Two fragments can be connected through two common atoms. c: Spiro Fusion: Connecting two fragments through 
the same atom.  d: Bridged Fusion: two fragments are connected through three or more fragments which form a 
bridged scaffold. e: Bridged Bipodal Connection: two connected fragments may not have any common atoms, and 
may be linked through intervening connection points resulting in a bridged scaffold. Black dots denote connectivity 
points. Individual fragments are indicated in either blue or green. Varied substituents or extended parts of NPs have 
been greyed for clarity. 
Figure 5: NP Scores of regioisomeric pyrrotropane and pyrroquinoline scaffolds. a: Designed (black) and 
reported6,43,44 (blue) pseudo-natural product scaffolds stemming from the combination of pyrrolidine, tropane, and 
tetrahydroquinoline fragments. The variable NP-scores demonstrate that pseudo-NPs may facilitate the exploration 
of chemical space. Black dots are used to denote the connectivity points. b: Illustrative examples of Design Principle 
1: Diverse Pseudo-NP scaffolds can be derived by combining two NP fragments using different connectivity 
patterns; 22: Pyrrotropane scaffold by edge fusion; 23: Pyrrotropane scaffold by spiro fusion  c: Design Principle 
2: Pseudo-NP scaffolds can be derived by combining two NP fragments by maintaining the same connectivity 
pattern e.g. spiro fusion, while changing the connectivity points between fragments; 24: Pyrrotropane scaffold by 
spiro fusion through C2 atom of pyrrolidine; 30: Pyrroquinoline scaffold by spiro fusion through C2 atom of 
tetrahydroquinoline and C3 atom of pyrrolidine; 31: Pyrroquinoline scaffold by spiro fusion through C2 atom of 
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tetrahydroquinoline and C2 atom of pyrrolidine;  d: Design Principle 3: Pseudo-NP scaffolds can be derived by 
combining more than two NP fragments using different connectivity patterns; 37: Indopyrroquinolinone scaffold 
by spiro fused oxindole and pyrrolidine, and edge fused dihydroquinolone. 
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